FDA approves first quadrivalent intradermal influenza vaccine
the ONA take:
Sanofi Pasteur has announced that the U.S. Food and Drug Administration (FDA) has approved Fluzone Intradermal Quadrivalent vaccine. A trivalent formulation of the vaccine has been available for 3 years, but the quadrivalent formulation will help to protect against four strains of influenza rather than three.
The vaccine is approved for adults aged 18 to 64 years for the prevention of infection by influenza A and B subtypes. The trivalent vaccine protects against two influenza A subtypes and only one influenza B subtype, but it is influenza B that is a common cause of morbidity and morality associated with influenza.
The most common adverse effects observed in clinical trials were erythema, headache, induration at the injection site, malaise, myalgia, pain, pruritus, and swelling. These reactions typically occurred within 3 days of vaccination and were mild to moderate in severity.
In addition, the intradermal vaccines is equally as effective as an intramuscular flu shot. Like other flu shots, the Fluzone Intradermal Quadrivalent vaccine should not be administered to patients with egg allergies or to anyone who has experienced a hypersensitivity reaction to a previous influenza vaccine.
The FDA has approved Fluzone Intradermal Quadrivalent vaccine for influenza.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|